{"PubmedArticle": [{"MedlineCitation": {"KeywordList": [], "GeneralNote": [], "OtherAbstract": [], "CitationSubset": ["IM"], "SpaceFlightMission": [], "OtherID": [], "InvestigatorList": [], "PMID": "33844145", "DateCompleted": {"Year": "2021", "Month": "11", "Day": "11"}, "DateRevised": {"Year": "2023", "Month": "01", "Day": "12"}, "Article": {"ArticleDate": [], "Language": ["eng"], "ELocationID": ["10.1007/s13318-021-00685-1"], "Journal": {"ISSN": "2107-0180", "JournalIssue": {"Volume": "46", "Issue": "3", "PubDate": {"Year": "2021", "Month": "May"}}, "Title": "European journal of drug metabolism and pharmacokinetics", "ISOAbbreviation": "Eur J Drug Metab Pharmacokinet"}, "ArticleTitle": "Cytochrome P450 Enzyme Inhibition and Herb-Drug Interaction Potential of Medicinal Plant Extracts Used for Management of Diabetes in Nigeria.", "Pagination": {"StartPage": "437", "EndPage": "450", "MedlinePgn": "437-450"}, "Abstract": {"AbstractText": ["The use of herbal medicines is common in Africa, and patients often use a combination of herbs and drugs. Concurrent herbal and pharmaceuticals treatments can cause adverse effects through herb-drug interactions (HDI). This study evaluated the potential risk of HDI for five medicinal plants, Vernonia amygdalina, Ocimum gratissimum, Moringa oleifera, Azadirachta indica, and Picralima nitida, using in vitro assays. Patients with diabetes and some other disease conditions commonly use these medicinal plants in Nigeria, and little is known regarding their potential for drug interaction, despite their enormous use.", "Crude extracts of the medicinal plants were evaluated for reversible and time-dependent inhibition (TDI) activity of six cytochrome P450 (CYP) enzymes using pooled human liver microsomes and cocktail probe-based assays. Enzyme activity was determined by quantifying marker metabolites' formation using liquid chromatography-mass spectrometry/mass spectrometry. The drug interaction potential was predicted for each herbal extract using the in vitro half-maximal inhibitory concentration (IC<sub>50</sub>) values and the percentage yield.", "O. gratissimum methanol extracts reversibly inhibited CYP 1A2, 2C8, 2C9 and 2C19 enzymes (IC<sub>50</sub>: 6.21 \u00b5g/ml, 2.96 \u00b5g/ml, 3.33 \u00b5g/ml and 1.37 \u00b5g/ml, respectively). Additionally, V. amygdalina methanol extract inhibited CYP2C8 activity (IC<sub>50</sub>: 5.71 \u00b5g/ml); P. nitida methanol and aqueous extracts inhibited CYP2D6 activity (IC<sub>50</sub>: 1.99 \u00b5g/ml and 2.36 \u00b5g/ml, respectively) while A. indica methanol extract inhibited CYP 3A4/5, 2C8 and 2C9 activity (IC<sub>50</sub>: 7.31 \u00b5g/ml, 9.97 \u00b5g/ml and 9.20 \u00b5g/ml, respectively). The extracts showed a potential for TDI of the enzymes when incubated at 200 \u00b5g/ml; V. amygdalina and A. indica methanol extracts exhibited TDI potential for all the major CYPs.", "The medicinal plants inhibited CYP activity in vitro, with the potential to cause in vivo HDI. Clinical risk assessment and proactive monitoring are recommended for patients who use these medicinal plants concurrently with drugs that are cleared through CYP metabolism."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, 7 Greenhouse Rd, Kingston, RI, 02881, USA."}, {"Identifier": [], "Affiliation": "Department of Clinical Pharmacy and Biopharmacy, Faculty of Pharmacy, University of Lagos, Lagos, Nigeria."}], "LastName": "Amaeze", "ForeName": "Ogochukwu", "Initials": "O"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT, USA."}], "LastName": "Eng", "ForeName": "Heather", "Initials": "H"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT, USA."}], "LastName": "Horlbogen", "ForeName": "Lauren", "Initials": "L"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT, USA."}], "LastName": "Varma", "ForeName": "Manthena V S", "Initials": "MVS"}, {"Identifier": ["0000-0002-0572-7001"], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Biomedical and Pharmaceutical Sciences, College of Pharmacy, University of Rhode Island, 7 Greenhouse Rd, Kingston, RI, 02881, USA. aslitt@uri.edu."}], "LastName": "Slitt", "ForeName": "Angela", "Initials": "A"}], "GrantList": [{"GrantID": "P42ES027706", "Acronym": "NH", "Agency": "NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "France", "MedlineTA": "Eur J Drug Metab Pharmacokinet", "NlmUniqueID": "7608491", "ISSNLinking": "0378-7966"}, "ChemicalList": [{"RegistryNumber": "0", "NameOfSubstance": "Cytochrome P-450 Enzyme Inhibitors"}, {"RegistryNumber": "0", "NameOfSubstance": "Hypoglycemic Agents"}, {"RegistryNumber": "0", "NameOfSubstance": "Plant Extracts"}], "MeshHeadingList": [{"QualifierName": [], "DescriptorName": "Chromatography, Liquid"}, {"QualifierName": ["administration & dosage", "isolation & purification", "pharmacology"], "DescriptorName": "Cytochrome P-450 Enzyme Inhibitors"}, {"QualifierName": ["drug therapy"], "DescriptorName": "Diabetes Mellitus"}, {"QualifierName": [], "DescriptorName": "Female"}, {"QualifierName": [], "DescriptorName": "Herb-Drug Interactions"}, {"QualifierName": [], "DescriptorName": "Humans"}, {"QualifierName": ["administration & dosage", "isolation & purification", "pharmacology"], "DescriptorName": "Hypoglycemic Agents"}, {"QualifierName": [], "DescriptorName": "In Vitro Techniques"}, {"QualifierName": [], "DescriptorName": "Inhibitory Concentration 50"}, {"QualifierName": [], "DescriptorName": "Male"}, {"QualifierName": ["metabolism"], "DescriptorName": "Microsomes, Liver"}, {"QualifierName": [], "DescriptorName": "Nigeria"}, {"QualifierName": ["administration & dosage", "pharmacology"], "DescriptorName": "Plant Extracts"}, {"QualifierName": ["chemistry"], "DescriptorName": "Plants, Medicinal"}, {"QualifierName": [], "DescriptorName": "Tandem Mass Spectrometry"}]}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Ogbera A, Dada O, Adeleye F, Jewo P. Complementary and alternative medicine use in diabetes mellitus. West Afr J Med. 2011;29(3):58\u201362."}, {"Citation": "Ezeome ER, Anarado AN. Use of complementary and alternative medicine by cancer patients at the University of Nigeria Teaching Hospital, Enugu, Nigeria. BMC Complement Altern Med. 2007. https://doi.org/10.1186/1472-6882-7-28 .", "ArticleIdList": ["10.1186/1472-6882-7-28", "17850665", "2034592"]}, {"Citation": "Ilomuanya MO, Okubanjo OO, Azubuike C, Oguntibeju A, Ajiboye D, Maduka C. Evaluation of the frequency of use of herbal drugs with concomitant administration of highly active antiretroviral therapy and its effect on medication adherence in two health care facilities in southwestern Nigeria. J AIDS HIV Res. 2017;9(1):8\u201316.", "ArticleIdList": ["10.5897/JAHR2016.0399"]}, {"Citation": "Amaeze OU, Aderemi-Williams RI, Ayo-Vaughan MA, Ogundemuren DA, Ogunmola DS, Anyika EN. Herbal medicine use among Type 2 diabetes mellitus patients in Nigeria: understanding the magnitude and predictors of use. Int J Clin Pharm. 2018;40(3):580\u20138.", "ArticleIdList": ["29721742", "10.1007/s11096-018-0648-2", "29721742"]}, {"Citation": "Chang HYA, Wallis M, Tiralongo E. Use of complementary and alternative medicine among people with type 2 diabetes in Taiwan: a cross-sectional survey. Evid Based Complement Altern Med. 2011. https://doi.org/10.1155/2011/983792 .", "ArticleIdList": ["10.1155/2011/983792"]}, {"Citation": "Mwangi J, Gitonga L. Perceptions and use of herbal remedies among patients with diabetes mellitus in Murang\u2019a North District, Kenya. Open J Clin Diagn. 2014;4:152\u201372.", "ArticleIdList": ["10.4236/ojcd.2014.43024"]}, {"Citation": "Singh J, Gautam C, Singh R. Self-medication with herbal remedies amongst patients of type 2 diabetes mellitus: a preliminary study. Indian J Endocrinol Metab. 2012;16(4):662\u20133.", "ArticleIdList": ["22837942", "3401782", "10.4103/2230-8210.98041"]}, {"Citation": "Jou J, Johnson PJ. Nondisclosure of complementary and alternative medicine use to primary care physicians: findings from the 2012 national health interview survey. JAMA Intern Med. 2016;176(4):545\u20136.", "ArticleIdList": ["26999670", "10.1001/jamainternmed.2015.8593", "26999670"]}, {"Citation": "Ben-Arye E, Attias S, Levy I, Goldstein L, Schiff E. Mind the gap: disclosure of dietary supplement use to hospital and family physicians. Patient Educ Couns. 2017;100(1):98\u2013103.", "ArticleIdList": ["27516439", "10.1016/j.pec.2016.07.037", "27516439"]}, {"Citation": "Gerber W, Steyn JD, Kotz\u00e9 AF, Hamman JH. Beneficial pharmacokinetic drug interactions: a tool to improve the bioavailability of poorly permeable drugs. Pharmaceutics. 2018;10(3):106.", "ArticleIdList": ["6161083", "10.3390/pharmaceutics10030106"]}, {"Citation": "Borse SP, Singh DP, Nivsarkar M. Understanding the relevance of herb-drug interaction studies with special focus on interplays. Porto Biomed J. 2019;4(2):e15.", "ArticleIdList": ["31595257", "6726296", "10.1016/j.pbj.0000000000000015"]}, {"Citation": "Kalgutkar AS, Obach AR, Maurer TS. Mechanism-based inactivation of Cytochrome P450 enzymes chemical mechanisms, structure-activity relationships, and relationship to clinical drug-drug interactions and idiosyncratic adverse drug reactions. Curr Drug Metab. 2007;8(5):407\u201347.", "ArticleIdList": ["17584015", "10.2174/138920007780866807", "17584015"]}, {"Citation": "Grimm SW, Einolf HJ, Hall SD, He K, Lim HK, Ling KHJ, et al. The conduct of in vitro studies to address time-dependent inhibition of drug-metabolizing enzymes: a perspective of the Pharmaceutical Research and Manufacturers of America. Drug Metab Dispos. 2009;37(7):1355\u201370.", "ArticleIdList": ["19359406", "10.1124/dmd.109.026716", "19359406"]}, {"Citation": "Kupiec T, Raj V. Fatal seizures due to potential herb-drug interactions with Ginkgo biloba. J Anal Toxicol. 2005;29(7):755\u20138.", "ArticleIdList": ["16419414", "10.1093/jat/29.7.755", "16419414"]}, {"Citation": "Mamindla S, Kvsrg P, Koganti B. Herb-drug interactions: an overview of mechanisms and clinical aspects. Int J Pharm Sci Res. 2016;7(9):3576\u201386."}, {"Citation": "Gurley BJ, Swain A, Hubbard MA, Williams DK, Barone G, Hartsfield F, et al. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John\u2019s wort, and Echinacea. Mol Nutr Food Res. 2008;52(7):755\u201363.", "ArticleIdList": ["18214849", "2562884", "10.1002/mnfr.200600300"]}, {"Citation": "Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, et al. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005;77(5):415\u201326.", "ArticleIdList": ["15900287", "1894911", "10.1016/j.clpt.2005.01.009"]}, {"Citation": "Showande JS, Fakeye TO, Tolonen A, Hokkanen J. In vitro inhibitory activities of the extract of Hibiscus sabdariffa L. (family Malvaceae) on selected cytochrome P450 isoforms. Afr J Tradit Complement Altern Med AJTCAM. 2013;10(3):533\u201340."}, {"Citation": "Gbolade AA. Inventory of antidiabetic plants in selected districts of Lagos State, Nigeria. J Ethnopharmacol. 2009;121(1):135\u20139.", "ArticleIdList": ["19013225", "10.1016/j.jep.2008.10.013", "19013225"]}, {"Citation": "Borokini TI, Ighere DA, Clement M, Ajiboye TO, Alowonle AA. Ethnobiological survey of traditional medicine practice for the treatment of piles and diabetes mellitus in Oyo State. J Med Plant Stud. 2013;1:30\u201340."}, {"Citation": "Ezuruike U, Prieto JM. Assessment of potential herb-drug interactions among Nigerian adults with type-2 diabetes. Front Pharmacol. 2016;10(7):248."}, {"Citation": "Al-awar MSA, Muaqeb AAA, Salih EMA. Antihyperglycemic and hypolipidemic effect of Azadirachta indica leaves aqueous extract in alloxan-induced diabetic male rabbits. Int J Pharm Biol Arch. 2018;9(1):47\u201351."}, {"Citation": "Ejike CECC, Awazie SO, Nwangozi PA, Godwin CD. Synergistic postprandial blood glucose modulatory properties of Vernonia amygdalina (Del.), Gongronema latifolium (Benth.) and Ocimum gratissimum (Linn.) aqueous decoctions. J Ethnopharmacol. 2013;149(1):111\u20136.", "ArticleIdList": ["23770031", "10.1016/j.jep.2013.06.009", "23770031"]}, {"Citation": "Khan W, Parveen R, Chester K, Parveen S, Ahmad A. Hypoglycemic potential of aqueous extract of Moringa oleifera leaf and in vivo GC-MS metabolomics. Front Pharmacol. 2017;12(8):577.", "ArticleIdList": ["10.3389/fphar.2017.00577"]}, {"Citation": "Okon U, Owo D, Udokang N, Udobang J, Ekpenyong C. Oral administration of aqueous leaf extract of Ocimum gratissimum ameliorates polyphagia, polydipsia and weight loss in streptozotocin-induced diabetic rats. Am J Med Med Sci. 2012;2(3):45\u20139.", "ArticleIdList": ["10.5923/j.ajmms.20120203.04"]}, {"Citation": "Okonta JM, Aguwa CN. Evaluation of the hypoglycemic activity of glycosides and alkaloids extracts of Picralima nitida stapf (Apocynaceae) seed. Int J Pharmacol. 2007;3(6):505\u20139.", "ArticleIdList": ["10.3923/ijp.2007.505.509"]}, {"Citation": "Zenebe MM, Dessie BK, Wana GG, Werkneh AA. Isolation, structural elucidation, and bioactivity studies of leaf extract of Vernonia amygdalina. Am J Appl Chem. 2015;3(1):14\u201320.", "ArticleIdList": ["10.11648/j.ajac.20150301.13"]}, {"Citation": "Akinmoladun AC, Ibukun EO, Afor E, Obuotor EM, Farombi EO. Phytochemical constituent and antioxidant activity of extract from the leaves of Ocimum gratissimum. Sci Res Essays. 2007;2(5):163\u20136."}, {"Citation": "Konmy BB, Olounlad\u00e9 PA, Allou SD, Azando EVB, Hounzangb\u00e9-Adot\u00e9 MS, Olounlad\u00e9 CPA. A review on phytochemistry and pharmacology of Moringa oleifera leaves (Moringaceae). J Pharmacogn Phytochem. 2016;5(5):325\u201330."}, {"Citation": "Erharuyi O, Falodun A, Langer P. Medicinal uses, phytochemistry and pharmacology of Picralima nitida (Apocynaceae) in tropical diseases: a review. Asian Pac J Trop Med. 2014;7:1\u20138.", "ArticleIdList": ["24418074", "10.1016/S1995-7645(13)60182-0", "24418074"]}, {"Citation": "Biswas K, Chattopadhyay I, Banerjee RK, Bandyopadhyay U. Biological activities and medicinal properties of neem (Azadirachta indica). Curr Sci. 2002;82(11):1336\u201345."}, {"Citation": "Orellana-Paucar A, Vintimilla-Rojas D. Interactions of clinical relevance associated with concurrent administration of prescription drug and food or medicinal plants: a systematic review protocol. Systems Control Found Appl. 2020. https://doi.org/10.1186/s13643-019-1259-2 .", "ArticleIdList": ["10.1186/s13643-019-1259-2"]}, {"Citation": "Ameade EPK, Ibrahim M, Ibrahim H-S, Habib RH, Gbedema SY. Concurrent use of herbal and orthodox medicines among residents of Tamale, Northern Ghana, who patronize hospitals and herbal clinics. Evid Based Complement Altern Med. 2018. https://doi.org/10.1155/2018/1289125 .", "ArticleIdList": ["10.1155/2018/1289125"]}, {"Citation": "Gupta RC, Chang D, Nammi S, Bensoussan A, Bilinski K, Roufogalis BD. Interactions between antidiabetic drugs and herbs: an overview of mechanisms of action and clinical implications. Diabetol Metab Syndr. 2017;9(1):1\u201312.", "ArticleIdList": ["10.1186/s13098-017-0254-9"]}, {"Citation": "Aluefua OF, Chika A, Muhammad AA, Usman A. Interactions between herbs and antidiabetic drugs: a systematic review. Res J Pharmacol. 2017;11(5):6\u201317."}, {"Citation": "Zimmerlin A, Trunzer M, Faller B. CYP3A time-dependent inhibition risk assessment validated with 400 reference drugs. Drug Metab Dispos. 2011;39(6):1039\u201346.", "ArticleIdList": ["21383203", "10.1124/dmd.110.037911", "21383203"]}, {"Citation": "Yates P, Eng H, Di L, Obach RS. Statistical methods for analysis of time-dependent inhibition of cytochrome P450 enzymes. Drug Metab Dispos. 2012;40(12):2289\u201396.", "ArticleIdList": ["22942318", "10.1124/dmd.112.047233", "22942318"]}, {"Citation": "Showande SJ, Fakeye TO, Kajula M, Hokkanen J, Tolonen A. Potential inhibition of major human cytochrome P450 isoenzymes by selected tropical medicinal herbs\u2014implication for herb\u2013drug interactions. Food Sci Nutr. 2019. https://doi.org/10.1002/fsn3.789 .", "ArticleIdList": ["10.1002/fsn3.789", "30680158", "30680158"]}, {"Citation": "Awortwe C, Bouic P, Masimirembwa C, Rosenkranz B. Inhibition of major drug metabolizing CYPs by common herbal medicines used by HIV/AIDS patients in Africa\u2013implications for herb-drug interactions. Drug Metab Lett. 2014;7(2):83\u201395.", "ArticleIdList": ["24475926", "4354708", "10.2174/1872312808666140129123210"]}, {"Citation": "Brantley SJ, Argikar AA, Lin YS, Nagar S, Paine MF. Herb-drug interactions: challenges and opportunities for improved predictions. Drug Metab Dispos. 2014;42(3):301\u201317.", "ArticleIdList": ["24335390", "3935140", "10.1124/dmd.113.055236"]}, {"Citation": "Gunes A, Dahl ML. Variation in CYP1A2 activity and its clinical implications: influence of environmental factors and genetic polymorphisms. Pharmacogenomics. 2008;9(5):625\u201337.", "ArticleIdList": ["18466106", "10.2217/14622416.9.5.625", "18466106"]}, {"Citation": "Thelingwani RS, Dhansay K, Smith P, Chibale K, Masimirembwa CM. Potent inhibition of CYP1A2 by Frutinone A, an active ingredient of the broad spectrum antimicrobial herbal extract from P. fruticosa. Xenobiotica. 2012;42(10):989\u20131000.", "ArticleIdList": ["22533317", "10.3109/00498254.2012.681077", "22533317"]}, {"Citation": "Fasinu PS, Gutmann H, Schiller H, James AD, Bouic PJ, Rosenkranz B. The potential of sutherlandia frutescens for herb-drug interaction. Drug Metab Dispos. 2013;41(2):488\u201397.", "ArticleIdList": ["23209194", "10.1124/dmd.112.049593", "23209194"]}, {"Citation": "Parkinson A, Ogilvie BW, Buckley DB, Kazmi F, Czerwinski M, Parkinson O. Biotransformation of xenobiotics. In: Casarett and Soull's toxicology, the basic science of poisons. 8th ed McGraw-Hill Education; 2013. p. 186\u2013363."}, {"Citation": "Thomford NE, Dzobo K, Chopera D, Wonkam A, Maroyi A, Blackhurst D, et al. In vitro reversible and time-dependent CYP450 inhibition profiles of medicinal herbal plant extracts Newbouldia laevis and Cassia abbreviata: Implications for herb-drug interactions. Molecules. 2016;21(2):211.", "ArticleIdList": ["6273559", "10.3390/molecules21020211"]}, {"Citation": "Yi JM, Kim YA, Lee YJ, Bang OS, Kim NS. Effect of an ethanol extract of Descurainia sophia seeds on Phase I and II drug metabolizing enzymes and P-glycoprotein activity in vitro. BMC Complement Altern Med. 2015. https://doi.org/10.1186/s12906-015-0965-0 .", "ArticleIdList": ["10.1186/s12906-015-0965-0", "26683337", "4683934"]}, {"Citation": "Kaspera R, Naraharisetti SB, Evangelista EA, Marciante KD, Psaty BM, Totah RA. Drug metabolism by CYP2C8.3 is determined by substrate dependent interactions with cytochrome P450 reductase and cytochrome b5. Biochem Pharmacol. 2011;82:681\u201391.", "ArticleIdList": ["21726541", "3159548", "10.1016/j.bcp.2011.06.027"]}, {"Citation": "Daly AK, Rettie AE, Fowler DM, Miners JO. Pharmacogenomics of CYP2C9: Functional and clinical considerations. J Personal Med. 2018;8(1):1.", "ArticleIdList": ["10.3390/jpm8010001"]}, {"Citation": "Lau C, Mooiman KD, Maas-Bakker RF, Beijnen JH, Schellens JHM, Meijerman I. Effect of Chinese herbs on CYP3A4 activity and expression in vitro. J Ethnopharmacol. 2013;149(2):543\u20139.", "ArticleIdList": ["23876595", "10.1016/j.jep.2013.07.014", "23876595"]}, {"Citation": "Chiangsom A, Lawanprasert S, Oda S, Kulthong K, Luechapudiporn R, Yokoi T, et al. Inhibitory and inductive effects of Phikud Navakot extract on human cytochrome P450. Drug Metab Pharmacokinet. 2016;31(3):210\u20137.", "ArticleIdList": ["27212065", "10.1016/j.dmpk.2016.04.002", "27212065"]}, {"Citation": "Gaedigk A, Sangkuhl K, Whirl-Carrillo M, Klein T, Steven LJ. Prediction of CYP2D6 phenotype from genotype across world populations. Genet Med. 2017;19(1):69\u201376.", "ArticleIdList": ["27388693", "10.1038/gim.2016.80", "27388693"]}, {"Citation": "Gopisankar MG. CYP2D6 pharmacogenomics. Egypt J Med Hum Genet. 2017;18(4):309\u201313.", "ArticleIdList": ["10.1016/j.ejmhg.2017.03.001"]}, {"Citation": "Monera TG, Wolfe AR, Maponga CC, Benet LZ, Guglielmo J. Moringa oleifera leaf extracts inhibit 6beta-hydroxylation of testosterone by CYP3A4. J Infect Dev Ctries. 2008;2(5):379\u201383.", "ArticleIdList": ["19745507", "5385924", "10.3855/jidc.201"]}, {"Citation": "Awortwe C, Manda V, Avonto C, Khan S, Khan I, Walker L, et al. In vitro evaluation of reversible and time-dependent inhibitory effects of Kalanchoe crenata on CYP2C19 and CYP3A4 Activities. Drug Metab Lett. 2015;9:48\u201362.", "ArticleIdList": ["25600201", "5656046", "10.2174/1872312809666150119110200"]}, {"Citation": "Taesotikul T, Navinpipatana V, Tassaneeyakul W. Selective inhibition of human cytochrome P450 1A2 by Moringa oleifera. J Pharmacol. 2010;32(1):256\u20138."}, {"Citation": "Zhou SF, Xue CC, Yu XQ, Li C, Wang G. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687\u2013710.", "ArticleIdList": ["18043468", "10.1097/FTD.0b013e31815c16f5", "18043468"]}, {"Citation": "VandenBrink BM, Isoherranen N. The role of metabolites in predicting drug-drug interactions: Focus on irreversible cytochrome P450 inhibition. Curr Opin Drug Discov Dev. 2010;13(1):66\u201377."}, {"Citation": "Mustap\u00edc D\u0160, Debeljak \u017d, Male\u0161 \u017d, Boj\u00edc M. The inhibitory effect of flavonoid aglycones on the metabolic activity of CYP3A4 enzyme. Molecules. 2018;23(10):2553.", "ArticleIdList": ["10.3390/molecules23102553"]}, {"Citation": "Atkinson A, Kenny JR, Grime K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab Dispos. 2005;23(10):2553."}, {"Citation": "Riley RJ, Wilson CE. Cytochrome P450 time-dependent inhibition and induction: advances in assays, risk analysis and modelling. Expert Opin Drug Metab Toxicol. 2015;11(4):557\u201372.", "ArticleIdList": ["25659570", "10.1517/17425255.2015.1013095", "25659570"]}, {"Citation": "Thomford NE, Dzobo K, Chopera D, Wonkam A, Skelton M, Blackhurst D, et al. Pharmacogenomics implications of using herbal medicinal plants on African populations in health transition. Pharmaceuticals. 2015;8(3):637\u201363.", "ArticleIdList": ["26402689", "4588186", "10.3390/ph8030637"]}, {"Citation": "Wong SG, Lee M, Wong BK. Single concentration loss of activity assay provides an improved assessment of drug\u2013drug interaction risk compared to IC50-shift. Xenobiotica. 2016;46(11):953\u201366.", "ArticleIdList": ["26956546", "10.3109/00498254.2016.1143139", "26956546"]}, {"Citation": "Kosaka M, Kosugi Y, Hirabayashi H. Risk assessment using cytochrome P450 time-dependent inhibition assays at single time and concentration in the early stage of drug discovery. J Pharm Sci. 2017;106(9):2838\u201346.", "ArticleIdList": ["10.1016/j.xphs.2017.04.077"]}], "ReferenceList": []}], "History": [{"Year": "2021", "Month": "4", "Day": "13", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "11", "Day": "12", "Hour": "6", "Minute": "0"}, {"Year": "2021", "Month": "4", "Day": "12", "Hour": "12", "Minute": "48"}], "PublicationStatus": "ppublish", "ArticleIdList": ["33844145", "10.1007/s13318-021-00685-1", "10.1007/s13318-021-00685-1"]}}], "PubmedBookArticle": []}